Drug Safety Update - March 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2024 (PDF).
This issue only contains a summary of letters to healthcare professionals in February. These generally related to supply issues and recalls but also includes a letter warning that pseudoephedrine has been very rarely associated with posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS), as reported last month.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « NICE Guidance - March 2024 | CKS Updates - March 2024 » |
Leave a Comment